Skip to search formSkip to main contentSkip to account menu

acquired hemophilia

Known as: acquired haemophilia 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Emicizumab is a recombinant humanized bispecific monoclonal antibody mimicking the cofactor function of activated factor VIII. 
Highly Cited
2016
Highly Cited
2016
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxis
We previously showed that pharmacokinetic‐guided prophylaxis (PKP) allows the dosing interval to be extended while maintaining a… 
Highly Cited
2013
Highly Cited
2013
Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A
It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated… 
Review
2012
Review
2012
Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey
Summary.  Frequent evaluation of haemophilia treatment is necessary to improve patient care. The 2010 Practice Patterns Survey… 
Review
2007
Review
2007
Current use of by‐passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors
Summary.  The ultimate goal of treatment for patients with inhibitory antibodies should be to permanently eradicate the inhibitor… 
Highly Cited
2005
Highly Cited
2005
Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept.
Acquired hemophilia (AH) is an extremely rare condition in which autoantibodies (inhibitors) against clotting factor VIII induce… 
Highly Cited
2005
Highly Cited
2005
Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical…
The safety and efficacy of a full-length sucrose-formulated recombinant factor VIII product (rFVIII-FS; Kogenate FS; Kogenate… 
2003
2003
Acquired haemophilia in HIV negative, HHV‐8 positive multicentric Castleman's disease: a case report
Abstract: Multicentric Castleman's Disease (MCD) is an atypical lymphoproliferative disorder, related to human herpesvirus 8 (HHV… 
Highly Cited
1998
Highly Cited
1998
When should prophylactic treatment in patients with haemophilia A and B start?— The German experience
Summary. Radiological and orthopaedic outcome in severe and moderate haemophilia A and B patients undergoing long‐term… 
Highly Cited
1991
Highly Cited
1991
Detection of three novel mutations in two haemophilia A patients by rapid screening of whole essential region of factor VIII gene
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License